Designing an HCV vaccine: a unique convergence of prevention and therapy?

Area of Science:

• Hepatology and Virology
• Immunology
• Vaccinology

Background:

• Direct-acting antivirals (DAAs) offer a cure for chronic Hepatitis C Virus (HCV) infection.
• However, widespread underdiagnosis and increasing transmission rates pose challenges to reducing the global liver disease burden.
• The long-term immunological consequences of DAA-induced viral clearance remain largely uninvestigated.

Purpose of the Study:

• To evaluate the potential of T cell-mediated immunity and neutralizing antibody vaccines in preventing HCV infection.
• To investigate whether DAA cure restores pre-existing HCV immunity in patients.
• To explore the therapeutic application of preventive vaccines in reversing immune dysfunction and preventing reinfection post-DAA treatment.

Main Methods:

• Initiation of the first human trial for an HCV preventive vaccine based on T cell immunity.
• Advanced development of an HCV vaccine designed to elicit neutralizing antibodies.
• Investigating immune restoration following DAA treatment for chronic HCV.

Main Results:

• The first human trial for a T cell-based HCV preventive vaccine is currently underway.
• A second vaccine targeting neutralizing antibodies is in advanced development.
• The study highlights the need to understand immune responses after DAA cure.

Conclusions:

• Preventive vaccines are crucial given the uncertainties surrounding DAA's impact on global HCV burden.
• Understanding immune restoration post-DAA cure is essential for future HCV control strategies.
• Preventive vaccines may hold therapeutic potential for immune restoration and protection against reinfection.